The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in plasma concentration of AVP-923 after dosing in combination with itraconazole
Timeframe: 16 Days
Change in plasma concentration of AVP-786 after dosing in combination with itraconazole
Timeframe: 16 Days